- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02607553
Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA
February 22, 2017 updated by: GenSpera, Inc.
G-202-006: An Open-Label, Single-Arm, Phase II Study to Evaluate the Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA
An open-label, single-arm, single-center Phase II study to evaluate the safety and activity of G-202 in patients with clear cell renal cell carcinoma that expresses PSMA
Study Overview
Detailed Description
Epithelial tumors, including clear cell renal cell carcinoma (RCC), have the ability to grow to only a finite size in the absence of vascularization.
RCC is characterized as a highly-vascularized tumor and inhibiting angiogenesis has the potential to impair tumor growth, including growth of RCC.
Therapeutic targeting of integral biological pathways in RCC, including those involving VEGF and mTOR, has produced robust clinical effects and revolutionized the treatment of metastatic RCC.
These approaches offers significant clinical benefit and sequential use of these agents has become the empirical standard of care.
However, complete or durable responses are uncommon and resistance develops after a median interval of 6-15 months.
This raises the pressing clinical need for additional therapeutic approaches for patients with metastatic clear cell RCC.
The purpose of this study is to investigate the approach of targeted delivery of cytotoxic chemotherapy with G-202 in patients with advanced, refractory RCC.
This study is based on prodrug tumor targeting, in which an inactive form of a toxic agent is administered systemically and gets activated in specific locations in the body, resulting in higher concentrations of the cytotoxic form at the tumor location.
G-202 is a prodrug that is activated by PSMA in the blood vessels of tumors, but not normal tissue; once activated, G-202 leads to disruption of intracellular calcium levels and subsequent induction of apoptosis.
Thus, G-202 is expected to bring about cell death in RCC and destroy the blood supply of RCC tumors.
This single-arm, open-label Phase II clinical trial will evaluate the safety and activity of G-202 in patients with RCC that expresses PSMA.
Study Type
Interventional
Enrollment (Actual)
2
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas Health Science Center, Houston
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female patients age ≥ 18 years
- Pathologic documentation of clear cell renal cell carcinoma
- Disease that is resistant or refractory to standard of care
- ECOG Performance Status < 2
- Most recent tissue biopsy demonstrates PSMA expression by immunohistochemical staining
- Adequate bone marrow function measured within 7 days prior to first infusion of G-202 (absolute peripheral granulocyte count > 1500 cells/m3; platelet count > 100,000 cells/m3)
- Adequate hepatic function measured within 7 days prior to first infusion of G-202 (Albumin ≥ 2.8 g/dL; AST and ALT ≤ 5 x ULN; Total bilirubin <2 mg/dL)
- Adequate renal function measured within 7 days prior to first infusion of G-202 (Proteinuria level ≤ 2 by urine dipstick; Serum creatinine ≤1.5 x ULN)
- Normal coagulation profile measured within 14 days prior to first infusion of G-202 (INR ≤ 2.3; aPTT ≤ 1.5 X ULN)
- No history of substantial non-iatrogenic bleeding diatheses. Use of anti-coagulants is limited to local use only (for control of central line patency)
- Patients must sign an informed consent indicating that they are aware of the investigational nature of the study and are willing to participate in the study
- Females of child-bearing potential and males with female partners of child-bearing potential must be willing to use acceptable methods of contraception to avoid pregnancy (for example, oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) beginning before the first infusion of G-202 and for 3 months after the last infusion of G-202
Exclusion Criteria:
- Uncontrolled cardiac, hepatic, renal, or neurologic/psychiatric disorder
- HIV positivity or history of chronic hepatitis B or C infection
- Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or history of congestive heart failure New York Heart Association (NYHA) class 3 or 4, unless a 2D echocardiogram or multi-gated acquisition scan (MUGA) performed within 3 months of enrollment demonstrates a left ventricular ejection fraction >45%
- History of another malignancy within the previous 5 years other than curatively treated non-melanoma skin cancer or or intraepithelial carcinoma of the cervix
- Surgical resection or major surgery within 4 weeks or stereotactic biopsy within 1 week of first G-202 treatment
- Treatment, chemotherapy, radiation therapy, immunotherapy, or investigational drug for the patient's renal cell cancer within 28 days prior to first infusion of G-202
- Currently requiring systemic administration of antibiotics or chronic administration of anti-viral agents
- Use of anti-coagulants is limited to local use for control of central line patency
- History or evidence of cardiac risk, including corrected QT interval on screening ECG > 470 msec, clinically significant uncontrolled arrhythmias or arrhythmia requiring treatment with the exceptions of atrial fibrillation and paroxysmal supraventricular tachycardia, history of acute coronary syndromes within 6 months prior to the first dose of study therapy (including myocardial infarction and unstable angina, coronary artery bypass graft, angioplasty, or stenting), any history of congestive heart failure with most recent ejection fraction < 45%
- Uncontrolled cardiac or coronary artery disease
- Uncontrolled hypertension (mean systolic BP ≥ 160 mm Hg and/or mean diastolic BP ≥ 100 mm Hg on 3 determinations 5 minutes apart while on 2 anti-hypertensive agents) or hypertension requiring treatment with more than 2 anti-hypertensive agents.
- Severe or uncontrolled medical disease, including uncontrolled diabetes, congestive heart failure, chronic renal disease or chronic pulmonary disease
- Severe gastrointestinal bleeding within 12 weeks of treatment with G-202
- Requirement for chronic use of medications known to be strong inhibitors or inducers of cytochrome (CYP3A4) iso-enzymes (Appendix 3) Note: If patients can stop receiving these medications, CYP3A4 inhibitors should be discontinued at least 7 days prior to starting treatment with G-202
- Known hypersensitivity to any study drug component including thapsigargin derivatives, polysorbate 20, or propylene glycol
- Any other condition, including concurrent medical condition, social circumstance or drug dependency, which in the opinion of the investigator could compromise patient safety and/or compliance with study requirements
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: G-202
G-202 administered by intravenous infusion on 3 consecutive days of a 28-day cycle
|
G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle until disease progression
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical activity
Time Frame: 8 weeks from first administration of G-202
|
Use RECIST criteria to assess the clinical activity of G-202 administered by intravenous infusion daily for 3 consecutive days of a 28-day cycle
|
8 weeks from first administration of G-202
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Robert Amato, D.O., University of Texas Health Sciences Center at Houston
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2016
Primary Completion (Actual)
December 1, 2016
Study Completion (Actual)
February 1, 2017
Study Registration Dates
First Submitted
November 16, 2015
First Submitted That Met QC Criteria
November 16, 2015
First Posted (Estimate)
November 18, 2015
Study Record Updates
Last Update Posted (Actual)
February 24, 2017
Last Update Submitted That Met QC Criteria
February 22, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- G-202-006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clear Cell Renal Cell Carcinoma
-
Celldex TherapeuticsTerminatedKidney Neoplasms | Metastatic Renal Cell Carcinoma | Ovarian Clear Cell Carcinoma | Papillary Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) | Clear-cell Renal Cell CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Guru SonpavdePfizer; Hoosier Cancer Research NetworkWithdrawnKidney Cancer | Clear-cell Renal Cell Carcinoma | RCC | Clear-cell Kidney CarcinomaUnited States
-
Peloton Therapeutics, Inc.Active, not recruitingA Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)Kidney Cancer | Clear Cell Renal Cell Carcinoma | Glioblastoma | Solid Tumor | Glioblastoma Multiforme | Advanced Solid Tumors | GBM | Solid Tumor, Adult | Solid Carcinoma | Glioblastoma, Adult | ccRCC | RCC, Clear Cell Adenocarcinoma | RCC | Renal Cell Carcinoma, Metastatic | Renal Cell Carcinoma Recurrent | Renal Cell...
-
Queen Mary University of LondonAstraZeneca; Vall d'Hebron Institute of OncologyActive, not recruitingRenal Clear Cell Carcinoma | Renal Papillary Cell CarcinomaUnited Kingdom
-
AmgenCompletedRenal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell AdenocarcinomaFrance, United States, Germany
-
University of WashingtonMerck Sharp & Dohme LLC; Prometheus LaboratoriesTerminatedMetastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Advanced Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell CancerUnited States
-
Telix International Pty LtdGrand Pharmaceutical (China) Co., Ltd.CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Cancer | Suspected Recurrent Renal Clear Cell CarcinomaChina
-
M.D. Anderson Cancer CenterActive, not recruitingMetastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8United States
-
Association Pour La Recherche des Thérapeutiques...CompletedClear-cell Metastatic Renal Cell Carcinoma | Clear-cell Renal CarcinomaFrance
Clinical Trials on G-202
-
Devalingam MahalingamGenSpera, Inc.No longer availableHepatocellular Carcinoma
-
GenSpera, Inc.WithdrawnProstate Cancer.United States
-
GenSpera, Inc.Saint John's Cancer InstituteWithdrawn
-
GenSpera, Inc.CompletedGlioblastoma MultiformeUnited States
-
GenSpera, Inc.CompletedAdvanced Solid TumorsUnited States
-
GenSpera, Inc.CompletedProstatic NeoplasmsUnited States
-
GenSpera, Inc.CompletedAdvanced Adult Hepatocellular CarcinomaUnited States
-
Immune-Onc TherapeuticsCalifornia Institute for Regenerative Medicine (CIRM)RecruitingCMML | AML With Monocytic DifferentiationUnited States
-
Evofem Inc.Neothetics, IncTerminatedCentral Abdominal Bulging
-
Shanghai Zerun Biotechnology Co.,LtdWalvax Biotechnology Co., Ltd.Active, not recruiting